Literature DB >> 9790789

Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.

I Konishi1, K Nanbu, M Mandai, Y Tsuruta, N Kataoka, Y Nagata, T Mori.   

Abstract

OBJECTIVE: To identify the clinicopathological and chemoresistant factors predicting the response to neoadjuvant chemotherapy and the patient prognosis in high-risk cervical carcinomas.
METHODS: We retrospectively reviewed 47 patients with locally advanced or bulky cervical carcinoma treated with two courses of intraarterial infusion of cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil (5-FU), followed by radical hysterectomy at our hospital between 1988 and 1995. Expressions of the chemoresistance-related proteins, such as P-glycoprotein, glutathione S-transferase pi (GST-pi), and proliferating cell nuclear antigen (PCNA) in the tumor cells, were examined by immunohistochemistry using pretreatment biopsy specimens. These results were compared with the chemotherapeutic response, which was evaluated by magnetic resonance imaging (MRI) and histopathology. Outcome of the patients was also studied.
RESULTS: Chemotherapeutic effect of either complete (CR) or partial (PR) response on MRI was obtained in 36 of the 47 (86%) patients. Poor response to chemotherapy was significantly correlated with P-glycoprotein expression (P < 0.005) and low PCNA labeling (P < 0. 05), but not GST-pi expression in the tumor cells. Independent prognostic factors for patient survival were parametrial involvement and lymph node metastasis. Neither the expression of GST-pi nor PCNA was correlated with the patient survival.
CONCLUSION: Assessment of the expression of P-glycoprotein and PCNA is potentially useful for the prediction of tumor response to neoadjuvant chemotherapy for cervical carcinomas. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790789     DOI: 10.1006/gyno.1998.5077

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.

Authors:  Paweł Surowiak; Verena Materna; Irina Kaplenko; Marek Spaczyński; Manfred Dietel; Hermann Lage; Maciej Zabel
Journal:  Virchows Arch       Date:  2005-06-21       Impact factor: 4.064

Review 2.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

3.  Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.

Authors:  Hidemichi Watari; Tatsuya Kanuma; Yoko Ohta; Mohamed Kamel Hassan; Takashi Mitamura; Masayoshi Hosaka; Takashi Minegishi; Noriaki Sakuragi
Journal:  Pathol Oncol Res       Date:  2010-01-08       Impact factor: 3.201

4.  Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells.

Authors:  Kexiu Zhu; Lihong Chen; Xiaobing Han; Jia Wang; Jue Wang
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

Review 5.  Molecular mechanisms of cisplatin resistance in cervical cancer.

Authors:  Haiyan Zhu; Hui Luo; Wenwen Zhang; Zhaojun Shen; Xiaoli Hu; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-06-07       Impact factor: 4.162

6.  Radiomic analysis for pretreatment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: A multicentre study.

Authors:  Caixia Sun; Xin Tian; Zhenyu Liu; Weili Li; Pengfei Li; Jiaming Chen; Weifeng Zhang; Ziyu Fang; Peiyan Du; Hui Duan; Ping Liu; Lihui Wang; Chunlin Chen; Jie Tian
Journal:  EBioMedicine       Date:  2019-08-06       Impact factor: 8.143

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.